Although the National Comprehensive Cancer Network (NCCN) guidelines of the United States recommend routine testing for PD-L1 expression in patients with diagnosed advanced NSCLC, and PD-L1 expression has been demonstrated as a reliable biomarker to predict benefits from immunotherapy (9, 10), there is lack of such recommendation in relevant Chinese treatment guidelines (11). The gene discussed is CD274; the disease is non-small cell lung carcinoma.